Skip to content

A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin

A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02715752
Enrollment
1000
Registered
2016-03-22
Start date
2016-01-31
Completion date
2016-03-31
Last updated
2016-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cytomegalovirus Infections, Epstein-Barr Virus Infections, Herpes Simplex Infections, Human Papillomavirus, Varicella-zoster Virus Infection

Brief summary

This study measured the changes in health-related complaints by analyzing charts of individuals, who are infected with a latent virus, who have used Gene-Eden-VIR/Novirin.

Detailed description

The medical community calls the movement from severe to mild disease and from mild to normal health, 'relieving symptoms', and the interventions that cause such movement, drugs, medications, or therapies. The alternative community calls the movement from normal health to superior health, 'boosting health' (or boosting the immune system, or improving your sex drive, or boosting any another well functioning physiological system), and the interventions that cause such movement, natural remedies, dietary supplements, complementary treatments, etc. In general, these interventions aim to achieve superior performance of a normal human body. Of course, boosting the body's normal performance improves many of its capabilities, such as higher resistance to diseases, faster recovery from fatigue, better mental concentration, etc. Each movement presents different objectives. Relieving symptoms represents the ability of an intervention to reduce the frequency, duration, and severity of a disease. In contrast, boosting health represents the ability of an intervention to increase the frequency, duration, and quality of a person's health. In the current study, the investigators would like to measure the changes in health-related complaints by analyzing charts of individuals, who are infected with latent virus, and who have used Gene-Eden-VIR/Novirin.

Interventions

DIETARY_SUPPLEMENTGene-Eden-VIR/Novirin

Sponsors

The Center for the Biology of Chronic Disease
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Latent viral infection with either HSV, HPV, VZV, EBV, or CMV * Taking Gene-Eden-VIR/Novirin

Exclusion criteria

* Use of other antiviral treatments

Design outcomes

Primary

MeasureTime frame
frequency of symptomsone year
duration of symptomsone year

Secondary

MeasureTime frame
time to first recurrenceone year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026